EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer

Elena Elez, Takayuki Yoshino, Lin Shen, Sara Lonardi, Eric Van Cutsem, Cathy Eng, Tae Won Kim, Harpreet Singh Wasan, Jayesh Desai iD, Fortunato Ciardiello, Rona Yaeger, Timothy S Maughan und 9 weitere

New England Journal of Medicine · 26.06.2025 · 392 (24) · 2425-2437

DOI: 10.1056/nejmoa2501912 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 26.06.2025. Verfasst von Elena Elez und 20 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron Hospital Campus, Barcelona. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carbamates, Cetuximab, Colorectal Neoplasms. Die Arbeit wurde bisher 185-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Pfizer, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarbamatesCetuximabColorectal NeoplasmsProto-Oncogene Proteins B-rafSulfonamidesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationNeoplasm MetastasisProgression-Free SurvivalTreatment OutcomeYoung AdultLeucovorinFluorouracilOrganoplatinum Compounds

Substanzen

BRAF protein, humanCarbamatesCetuximabencorafenibProto-Oncogene Proteins B-rafSulfonamidesLeucovorinFluorouracilOrganoplatinum Compounds

Autor:innen und Institutionen

  • Vall d'Hebron Hospital Campus, Barcelona.
  • Vall d'Hebron Institute of Oncology, Barcelona.
  • National Cancer Center Hospital East, Kashiwa, Japan.
  • Beijing Cancer Hospital, Beijing.
  • Veneto Institute of Oncology, IRCCS, Padua, Italy.
  • University Hospitals Gasthuisberg Leuven, Leuven, Belgium.

ORCID-Profile: Jayesh Desai, Scott Kopetz

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Pfizer, Inc.
  • Clinical Center

Zitieren

APA

Elez, E., Yoshino, T., Shen, L., Lonardi, S., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., Yaeger, R., Maughan, T. S., Morris, V. K., Wu, C., Usari, T., Laliberte, R., Dychter, S. S., Zhang, X., Tabernero, J., …, & BREAKWATER Trial Investigators (2025). Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer. New England Journal of Medicine, 392(24), 2425-2437. https://doi.org/10.1056/nejmoa2501912

Vancouver

Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, et al. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer. New England Journal of Medicine. 2025;392(24):2425-2437. doi:10.1056/nejmoa2501912

BibTeX
@article{Elez2025,
  author = {Elez, Elena and Yoshino, Takayuki and Shen, Lin and Lonardi, Sara and Van Cutsem, Eric and Eng, Cathy and Kim, Tae Won and Wasan, Harpreet Singh and Desai, Jayesh and Ciardiello, Fortunato and Yaeger, Rona and Maughan, Timothy S and Morris, Van K and Wu, Christina and Usari, Tiziana and Laliberte, Robert and Dychter, Samuel S and Zhang, Xiaosong and Tabernero, Josep and Kopetz, Scott and BREAKWATER Trial Investigators, BREAKWATER Trial Investigators},
  title = {Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {24},
  pages = {2425--2437},
  doi = {10.1056/nejmoa2501912}
}
Kostenlos starten →